임상 한눈에 보기

• 9건의 ClinicalTrials.gov 임상 기록
• 임상시험 탭에서 enrollment 상위 목록을 불러올 수 있습니다
• 모집 중 3건 · 완료/종료 4건
• Phase: Phase 2 · Phase 1 · Phase 1, Phase 2
• Status: Active, not recruiting · Completed · Suspended…
• 주요 endpoint: PSA50 is the primary endpoint for the mCRPC cohort. Objective Response Rate (ORR) as assessed by Response Evaluation Criteria in Solid Tumours (RECIST) version 1 criteria is the primary endpoint for gynecological malignancy cohorts · Determine the safety and tolerability profile of XmAb20717 · To establish the efficacy of XmAb20717 as measured by overall response rate. · Incidence of treatment-emergent adverse events (safety and tolerability of vudalimab) · Objective response rate (RECIST 1.1
• 등록 대상자(표본 합산): 약 645명

수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.